A Clinical Study on Immunogenicity Persistence of Adsorbed 5-component Acellular Pertussis, Diphtheria and Tetanus Combined Vaccine

Inclusion Criteria:

• Participants in the 6-11-year-old, 12-17-year-old, and ≥18-year-old groups from the Phase I clinical trial of the adsorbed acellular pentavalent (five-component) DTP-polio combined vaccine (for individuals aged 6 and older) (Protocol No.: CTP-Tdcp-001) who were included in the protocol-defined analysis set;
• Willingness to provide identification documents;
• Informed consent must be obtained from the trial participant and/or guardian and/or authorized representative, and the informed consent form must be signed;
• The trial participant and/or guardian and/or authorized representative must be able and willing to comply with the requirements of the clinical study protocol and be able to complete the full course of study follow-up.

Exclusion Criteria:

• Received another DTP-type vaccine after completing the CTP-Tdcp-001 study;
• Developed a DTP-related illness since the completion of the CTP-Tdcp-001 study;
• Has a coagulation disorder;
• In the investigator's judgment, the participant has any other factors that make them unsuitable for participation in the clinical trial.